SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for the Treatment of Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for the Treatment of Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

  • Org Study ID: SCRI GU 124
  • Secondary ID:
  • NCT ID: NCT02887248
  • NCT Alias:
  • Sponsor: SCRI Development Innovations, LLC - Other
  • Source: SCRI Development Innovations, LLC

Brief Summary

The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or cisplatin-incurable advanced urothelial carcinoma (UC).

Detailed Description

This open-label, non-randomized phase II trial evaluates the efficacy and toxicity of
first-line treatment with a combination of gemcitabine and nab-paclitaxel, followed by
maintenance therapy with nab-paclitaxel alone in patients with metastatic or locally advanced
unresectable urothelial cancer. Two groups of patients are eligible: (1) patients who are
poor candidates for treatment with cisplatin, and (2) patients with visceral metastases who
are incurable and unlikely to derive long-term benefit from treatment with cisplatin-based
regimens. Eligible patients will receive a minimum of 3 cycles and up to 6 cycles of
treatment with the gemcitabine/nab-paclitaxel combination. Patients having an objective
response or stable disease will continue maintenance treatment with single-agent
nab-paclitaxel until disease progression, intolerable toxicity, or patient decision to
discontinue treatment. Up to 55 patients are planned for enrollment.

Overal Status Start Date Phase Study Type
Recruiting January 12, 2017 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: 6 month progression-free survival (PFS6)

Primary Outcome 1 - Time Frame: up to 26 weeks


  • Urothelial Carcinoma
  • Bladder Cancer
  • Transitional Cell Carcinoma



Inclusion Criteria:

1. Histologically confirmed diagnosis of urothelial carcinoma (UC) that is either
metastatic (any N+ M1) or locally advanced and unresectable (T4bN0). A component of
urothelial (transitional cell) carcinoma is required.

2. Two groups of patients are eligible:

1. Poor candidates for cisplatin-based chemotherapy based on the presence of ≥ 1 the

- Glomerular filtration rate of 30-60 ml/min (Cockcroft-Gault formula)

- ECOG performance status score of 2

- Hearing loss (trouble communicating with hearing aids or hearing loss at ≤ 3

- Grade ≥3 heart failure

- Age ≥80 years

- Other concurrent illness which may make the patient a poor candidate for
receiving cisplatin.

Note: Enrollment of patients with 2 or more of these criteria should occur only
after careful consideration by the treating physician regarding the patient's
ability to tolerate combination chemotherapy.


2. Poor prognosis and defined as cisplatin-incurable due to the presence of
metastasis to at least one visceral site (these patients are not required to have
any of the cisplatin-ineligibility criteria).

- ECOG performance status score of 0, 1, or 2.

3. Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1.

4. Patients with brain metastases are allowed if treatment was completed at least 4 weeks
prior to study treatment, neurologic symptoms are minimal and stable during the
preceding 4 weeks, and maintenance dexamethasone is not required.

5. Adequate hematologic, liver and kidney function.

6. Willingness and ability to comply with study requirements and give written informed

Exclusion Criteria:

1. Previous systemic chemotherapy for UC with the exception of perioperative (neoadjuvant
or adjuvant) treatment or treatment with concurrent chemoradiation for locally
advanced disease. All of these treatments must have been completed more than 1 year

2. Presence of small-cell or sarcomatoid component in tumor histology.

3. Women who are pregnant or breast-feeding.

4. Major surgical procedures ≤28 days of beginning study drug, or minor surgical
procedures ≤7 days. No waiting required following port-a-cath placement.

5. Cardiac diseases currently or within the last 6 months:

6. Inadequately controlled hypertension.

7. Currently receiving treatment with therapeutic doses of warfarin sodium. (A maximum
daily dose of 1 mg will be permitted for port line patency. Low molecular weight
heparin is allowed.)

8. Serious active infection at the time of treatment, or another serious underlying
medical condition that would impair the ability of the patient to receive protocol

9. Known diagnosis of human immunodeficiency virus, hepatitis B or hepatitis C (screening
for these diseases is not required.).

10. Presence of other active cancers, or history of treatment for invasive cancer ≤5 years
previously. Patients with Stage I cancer who have received definitive local treatment
and are considered unlikely to recur are eligible. All patients with previously
treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with
history of non-melanoma skin cancer.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: John Hainsworth, MD

Role: Study Chair

Affiliation: SCRI Development Innovations, LLC

Overall Contact

Name: SCRI Development Innovations

Phone: 1-877-MY-1-SCRI



Facility Status Contact
Florida Cancer Specialists - South
Fort Myers, Florida 33916
United States
Florida Cancer Specialists-North
Saint Petersburg, Florida 33705
United States
Florida Cancer Specialists-East
West Palm Beach, Florida 33401
United States
Tennessee Oncology
Nashville, Tennessee 37203
United States
Center for Cancer and Blood Disorders
Fort Worth, Texas 76104
United States